Camp4 Therapeutics Corp (CAMP)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Research and collaboration revenue | 1,497 | 858 | - | |
| Research and development | 10,343 | 10,146 | 9,702 | |
| General and administrative | 4,182 | 3,812 | 3,814 | |
| Total operating expenses | 14,525 | 13,958 | 13,516 | |
| Loss from operations | -13,028 | -13,100 | -13,516 | |
| Other nonoperating expense | - | - | 62 | |
| Other income (expense) | -12 | 79 | - | |
| Interest income | 453 | 588 | 94 | |
| Total other income, net | 441 | 667 | 32 | |
| Net loss attributable to common stockholders | -12,587 | -12,433 | -13,484 | |
| Comprehensive loss | -12,587 | -12,433 | -13,484 | |
| Net loss per share attributable to common stockholders, basic, (in dollars per share) | -0.62 | -0.62 | -24.19 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.62 | -0.62 | -24.19 | |
| Weighted-average common shares outstanding, diluted (in shares) | 20,159,666 | 20,152,872 | 557,437 | |
| Weighted-average shares of common stock outstanding, basic (in shares) | 20,159,666 | 20,152,872 | 557,437 | |